Desktop Banner Mobile Banner
Close

Congratulations to the 2018 Nobel Prize in Physiology or Medicine Winners Read More

30 Breakthroughs in Immunotherapy

Let's spread the word about Immunotherapy! Click to share this page with your community.

Discover CRI's impact on the development of today’s (and tomorrow’s) immunotherapy treatments with 30 scientific breakthroughs. Every day in June, we’re sharing a different advancement based on innovative, CRI-funded research, supporting our goal to harness our immune system’s power to control and potentially cure all types of cancers. Follow us on Twitter @CancerResearch #CIM18 for daily updates.   

30 Days of CRI Impact

Characterized natural anti-tumor immune responses in cancer patients

1976: Drs. Hiroshi Shiku, Herbert Oettgen, and Lloyd J. Old

Created an antibody that can detect p53 that’s been useful in studying this important tumor suppressor protein

1981: Drs. Wolfgang Dippold and Lloyd J. Old

Identified patient traits that could predict responses to checkpoint immunotherapy

2014: Dr. Antoni Ribas

Shed light on an important marker associated with T cells

1979: Drs. John Pesando and Stuart Schlossman

Revealed that the antitumor activity of antibodies depends upon the types of FcR receptors the antibodies bind to

2000: Drs. Terris Towers and Jeffrey Ravetch

Discovered how the immune system can create trillions of customized antibodies

1983: Dr. Susumu Tonegawa

Discovered and described the phenomenon of "cancer immunoediting"

2001: Drs Vijay Shankaran, Allen Bruce, Hiroki Ikeda, and Robert Schreiber

Identified and isolated the portion of the T cell receptor that binds to MHCII proteins

1987: Drs. Marcia Blackman and Philippa Marrack

Demonstrated that dendritic cells promote T cell growth and adaptive immune responses

1983: Drs. Jonathan Austyn and Ralph Steinman

Revealed how the β-catenin pathway enables melanoma to evade immune responses

2015: Drs. Stefani Spranger and Thomas Gajewski

Demonstrated that the CTLA-4 checkpoint pathway regulates immune responses against self-tissues

1995: Drs. Frank Borriello and Arlene Sharpe

Provided early proof that checkpoint immunotherapy unleashes T cells against mutated tumor antigens

2014: Drs. Matthew Gubin and Robert Schreiber

Revealed that targeting the PD-1 immune checkpoint restores the activity of “exhausted” T cells

2006: Drs. E. John Wherry, David Masopust, and Rafi Ahmed

Developed nanobodies that enabled them to monitor “killer” T cells and predict immunotherapy responses

2017: Drs. Mohammad Rashidian and Hidde Ploegh

Revealed that the CD40 pathway is required for adaptive immunity

2004: Drs. Kang Liu and Ralph Steinman

Identified mutations associated with resistance to checkpoint immunotherapy 
 
 

2016: Drs. Ton Schumacher, Roger Lo, and Antoni Ribas

Revealed that FOXP3 serves as the master molecular switch for regulatory T cell development

2003: Drs. Jason Fontenot and Alexander Rudensky

Showed that targeting macrophages can convert “cold” tumors into “hot” ones that the immune system attacks more vigorously

2018: Dr. Susan Kaech

Revealed a second “don’t eat me!” signal that cancer cells use to protect themselves from the immune system

2017: Drs. Roy Maute and Irving Weissman

Performed one of the first successful uses of adoptive T cell therapy with patient-derived immune cells in patients with melanoma

2002: Dr. Cassian Yee

Revealed that natural killer cells protect against tumor formation through the NKG2D pathway

2006: Drs. Yoshihiro Hayakawa and Mark Smyth

Showed that central memory T cells provide superior, persistent protection against disease

2003: Drs. E. John Wherry, David Masopust, and Rafi Ahmed

Showed that regional delivery of CAR T cells improves their activity against mesothelioma

2014: Dr. Michel Sadelain

Found that vaccines against NY-ESO-1 were associated with improved survival in patients with aggressive ovarian cancer

2017: Drs. Sacha Gnjatic and Kunle Odunsi

Revealed how certain bacterial components stimulate the immune system

1974: Dr. Edgar Lederer

Proved that next generation sequencing could be used to characterized tumor neoantigens

2012: Drs. Matthew Vesely and Robert Schreiber

Showed that intestinal bacteria direct the development of specialized immune cells

2008: Drs. Nicolas Manel and Dan Littman

Discovered that heat shock proteins carry tumor-associated antigens that help stimulate immune responses against cancer

1993 Dr. Pramod Srivastava

Revealed the potential benefits of immunotherapy prior to surgery in lung cancer patients

2018: CRI-SU2C Immunology Dream Team

Discovered that certain intestinal bacteria make checkpoint immunotherapy more effective in mice
 

2015 Drs. Leticia Corrales and Thomas Gajewski

*Immunotherapy results may vary from patient to patient.

Contact Us

Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111

(800) 992-2623(212) 832-9376Staff Directory

Stay Connected with CRI

Follow us
Top